Spectrum Pharmaceuticals Reports Strong Revenues And Profits For Third Quarter; Revenues Of $69 Million Up 35% Over Last Year And GAAP Diluted EPS Of $0.33 And Non-GAAP Diluted EPS Of $0.42

Third Quarter Highlights

Product Diversification and Fiscal Discipline

• Three commercial products – including recently acquired FOLOTYN® (pralatrexate injection) – plus two additional late-stage products.
• All three products can be effectively promoted by a single sales representative.
• Realization of synergies in acquisition of Allos Therapeutics; integration continues, with further benefits and cost savings expected in 2013.
• Decentralizing key decision-making in commercial sales team to better meet the needs of our customers regionally.

Continuing to Attract Top Talent

• Ken Keller, Executive Vice President and Chief Operating Officer
• Joe Turgeon, Senior Vice President, Sales & Commercial Operations.

Conference Call

Wednesday, November 7, 2012 @ 1:30 p.m. Eastern/10:30 a.m. Pacific
Domestic:						[phone], Conference ID# 55115957
International:						[phone], Conference ID# 55115957

For interested individuals unable to join the call, a replay will be available from November 7, 2012 @ 4:30 p.m. ET/1:30 p.m. PT through November 21, 2012 until 11:59 p.m. ET/8:59 p.m. PT.

Domestic Replay Dial-In #:											[phone], Conference ID# 55115957
International Replay Dial-In #:											[phone], Conference ID# 55115957

This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: www.sppirx.com on November 7, 2012 at 1:30 p.m. Eastern/10:30 a.m. Pacific.

On the conference call, management will review the financial results, provide an update on the Company's business and discuss expectations for the future.

« First ‹ Previous 1 2 3 4 5 6 7 8 Next › Last »